Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K.

Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x. Epub 2010 Sep 22.

PMID:
20859679
2.

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L, Giannini A, Di Leo A.

Breast Cancer Res Treat. 2009 Dec;118(3):523-30. doi: 10.1007/s10549-009-0461-7. Epub 2009 Jul 12.

PMID:
19597704
3.
4.

Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.

Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM.

Breast Cancer Res Treat. 2011 Sep;129(2):451-8. doi: 10.1007/s10549-011-1645-5. Epub 2011 Jun 28.

PMID:
21710134
5.

Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.

Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, Shariat SF, Fisch M, Pantel K, Riethdorf S.

Eur Urol. 2012 Apr;61(4):810-7. doi: 10.1016/j.eururo.2012.01.017. Epub 2012 Jan 20.

PMID:
22277196
6.

Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.

Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT.

Clin Breast Cancer. 2010 Oct 1;10(5):392-7. doi: 10.3816/CBC.2010.n.052.

PMID:
20920984
7.

Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.

J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.

PMID:
17954712
8.

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.

Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2009 Oct;117(3):525-34. doi: 10.1007/s10549-008-0239-3. Epub 2008 Nov 19. Erratum in: Breast Cancer Res Treat. 2009 Oct;117(3):539.

PMID:
19016323
9.

A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients.

Kim SJ, Masago A, Tamaki Y, Akazawa K, Tsukamoto F, Sato J, Ozawa T, Tsujino Y, Noguchi S.

Breast Cancer Res Treat. 2011 Aug;128(3):765-73. doi: 10.1007/s10549-011-1603-2. Epub 2011 Jun 1.

PMID:
21630023
10.

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.

Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN.

Breast Cancer Res Treat. 2013 Jan;137(2):503-10. doi: 10.1007/s10549-012-2382-0. Epub 2012 Dec 28.

PMID:
23271327
11.

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.

Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T; DETECT study group..

Breast Cancer Res. 2012 Aug 15;14(4):R118. doi: 10.1186/bcr3243.

12.

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.

Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu H, Li S, Hu Z, Wu S, Liu B, Jiang Z.

BMC Cancer. 2013 Apr 23;13:202. doi: 10.1186/1471-2407-13-202.

13.

CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer.

Tunca B, Egeli U, Cecener G, Tezcan G, Gökgöz S, Tasdelen I, Bayram N, Tolunay S, Umut G, Demirdogen E, Erturk E, Ak S, Cetintas S, Evrensel T.

Tumori. 2012 Mar-Apr;98(2):243-51. doi: 10.1700/1088.11937.

PMID:
22677992
14.

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.

Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE.

Ann Surg Oncol. 2007 Dec;14(12):3359-68. Epub 2007 Sep 29.

PMID:
17906897
15.

Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.

Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M.

Int J Cancer. 2012 Apr 1;130(7):1590-7. doi: 10.1002/ijc.26111. Epub 2011 Nov 30.

16.

Detection of circulating tumor cells in metastatic breast cancer patients.

Sanislo L, Vertakova-Krakovska B, Kuliffay P, Brtko J, Galbava A, Galbavy S.

Endocr Regul. 2011 Jul;45(3):113-24.

PMID:
21793623
18.

Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series.

Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT.

Int J Clin Oncol. 2011 Oct;16(5):596-600. doi: 10.1007/s10147-010-0173-3. Epub 2011 Jan 6.

PMID:
21210173
19.

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.

Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K.

Clin Cancer Res. 2010 May 1;16(9):2634-45. doi: 10.1158/1078-0432.CCR-09-2042. Epub 2010 Apr 20.

20.

HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.

Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, Brandt B.

Clin Cancer Res. 2006 Mar 15;12(6):1715-20.

Supplemental Content

Support Center